Company profile: Ionix Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of discovery and development of new analgesic medicines for the treatment of acute and chronic pain. Based in Cambridge, UK, Ionix Pharmaceuticals leverages proprietary drug targets and state-of-the-art chemistry to alleviate pain associated with trauma and operative procedures.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ionix Pharmaceuticals
Sania Therapeutics
HQ: United Kingdom
Website
- Description: Provider of precision genetic neuromodulation therapies for nervous system disorders, using chemogenetics to safely and accurately alter neuronal activity and stabilize faulty electrical signaling. Offers AAV-based delivery systems with proprietary human-centric platforms to target specific cells. Lead program addresses hyperexcitable motor dysfunctions, such as spasticity, by targeting neural subtypes for long-term therapeutic benefit.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sania Therapeutics company profile →
Nexstim
HQ: Finland
Website
- Description: Provider of image-guided transcranial magnetic stimulation solutions, including SmartFocus nTMS for precise targeting in treating major depressive disorder and for pre-surgical brain mapping; NBS System 5 for navigated mapping of speech and motor cortices (FDA approval, CE marking); and NBS System 6 for major depressive disorder and chronic neuropathic pain (FDA clearance, CE marking; available in the US and Europe).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nexstim company profile →
NLS Pharmaceutics
HQ: Switzerland
Website
- Description: Provider of clinical-stage drug development focused on neurobehavioral and neurocognitive disorders and their pharmacognosia, using a patient-centered, target-specific approach via collaborations with industry and academia. Products include Quilience, an extended-release mazindol for excessive daytime sleepiness and cataplexy in narcolepsy, and Nolazol, a controlled-release mazindol for ADHD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NLS Pharmaceutics company profile →
Moberg
HQ: United States
Website
- Description: Provider of medical devices and neurodiagnostic solutions, including RetCam Envision pediatric ophthalmic imaging, Otoscan 3D ear scanning for auditory assessments, Natus NeuroWorks EEG analysis software, UltraPro S100 EMG/NCS/EP neurodiagnostic systems, and dedicated service and support for efficient workflows and optimal patient outcomes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Moberg company profile →
Javelin Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical research, development, and commercialization of products for the pain management market primarily in the United States and Europe, focusing on treatments for various pain disorders ranging from acute and episodic moderate-to-severe pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Javelin Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ionix Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ionix Pharmaceuticals
2.2 - Growth funds investing in similar companies to Ionix Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ionix Pharmaceuticals
4.2 - Public trading comparable groups for Ionix Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →